Phase II Study of Dovitinib (TKI-258) in Progressive, Well-Differentiated Pancreatic Neuroendocrine Tumors With and Without Prior VEGF-Inhibitor Therapy
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2017
At a glance
- Drugs Dovitinib (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 29 Jul 2015 Status changed from active, no longer recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 16 Nov 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.